Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

Insulin: The Receptor and Signaling Pathways

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.

Diabetes, obesity & metabolism·2015

Same author

G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1.

Diabetologia·2012

Same author

Glucolipotoxicity age-dependently impairs beta cell function in rats despite a marked increase in beta cell mass.

Diabetologia·2010

Same author

Lipid receptors and islet function: therapeutic implications?

Diabetes, obesity & metabolism·2009

Same author

[2006 Apollinaire Bouchardat Award. Fatty acids and pancreatic beta cell function].

Journees annuelles de diabetologie de l'Hotel-Dieu·2006

Same author

Gluco-lipotoxicity of the pancreatic beta cell.

Annales d'endocrinologie·2004

Search research articles

Related Experiment Video

Updated: May 16, 2026

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function

Published on: May 4, 2021

Lipotoxicity impairs incretin signalling.

¹Montreal Diabetes Research Center, CRCHUM, Technopôle Angus, 2901 Rachel Est, Montréal, QC, Canada. vincent.poitout@umontreal.ca

|November 29, 2012

Summary

Lipotoxicity, like glucotoxicity, impairs incretin receptor function in type 2 diabetes. Combining lipid-lowering drugs with incretin therapies may enhance treatment effectiveness for type 2 diabetes.

Area of Science:

Endocrinology
Metabolic Diseases
Pharmacology

Background:

Incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), enhance glucose-dependent insulin secretion.
Incretin-based therapies are crucial for managing type 2 diabetes.
The efficacy of incretin therapies is reduced in type 2 diabetes due to impaired incretin receptor signaling, partly caused by glucotoxicity.

Purpose of the Study:

To investigate the impact of lipotoxicity on incretin receptor expression and signaling in insulin-secreting cells and islets.
To evaluate the combined effects of lipid-lowering drugs and incretin-based therapies in animal models of diabetes.

Main Methods:

Utilized animal models of diabetes.
Assessed the effects of co-administering lipid-lowering drugs with dipeptidyl peptidase-4 (DPP-4) inhibitors or GLP-1 agonists.

More Related Videos

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

Related Experiment Videos

Last Updated: May 16, 2026

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function

Published on: May 4, 2021

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

Monitored glucose tolerance and beta cell mass.

Main Results:

Lipotoxicity, in addition to glucotoxicity, negatively affects incretin receptor expression and signaling.
Co-administration of lipid-lowering drugs with incretin-based therapies improved glucose tolerance in diabetic animal models.
Enhanced beta cell mass was observed with the combined treatment approach.

Conclusions:

Both glucotoxicity and lipotoxicity contribute to the diminished efficacy of incretin-based therapies in type 2 diabetes.
Restoring normal lipid levels may improve the effectiveness of incretin-based treatments.
This study highlights a potential strategy to enhance type 2 diabetes management by addressing both lipid and glucose metabolism.